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Background: The aim of this study was to investigate the intestinal mucus-penetrating properties 
and intestinal cellular uptake of two types of liposomes modified by Pluronic F127 (PF127).
Methods: The two types of liposomes, ie, PF127-inlaid liposomes and PF127-adsorbed 
liposomes, were prepared by a thin-film hydration method followed by extrusion, in which 
coumarin 6 was loaded as a fluorescence marker. A modified Franz diffusion cell mounted 
with the intestinal mucus of rats was used to study the diffusion characteristics of the two types 
of PF127 liposomes. Cell uptake studies were conducted in Caco-2 cells and analyzed using 
confocal laser scanning microcopy as well as flow cytometry.
Results: The diffusion efficiency of the two types of PF127-modified liposomes through 
intestinal rat mucus was 5–7-fold higher than that of unmodified liposomes. Compared with 
unmodified liposomes, PF127-inlaid liposomes showed significantly higher cellular uptake 
of courmarin 6. PF127-adsorbed liposomes showed a lower cellular uptake. Moreover, and 
interestingly, the two types of PF127-modified liposomes showed different cellular uptake 
mechanisms in Caco-2 cells.
Conclusion: PF127-inlaid liposomes with improved intestinal mucus-penetrating ability and 
enhanced cellular uptake might be a potential carrier candidate for oral drug delivery.
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Introduction
Liposomal formulations have for many years been among the most promising nano-
carriers for drug delivery and have been widely studied for many years.1–5 These 
vesicular carriers composed of one or more phospholipid bilayers are able to carry 
both hydrophilic and hydrophobic drug molecules due to their amphiphilic nature. 
They are easily biodegradable as well as biocompatible, and have strong similarities 
in composition to a biomembrane. However, liposomes are not as yet an ideal vehicle 
for oral drug delivery. One of the limitations of this system lies in the poor mucus-
penetrating properties of liposomes.6,7 Owing to the hydrophobic properties of liposomes, 
they can be easily trapped or wiped by the mucus blanket, which greatly compromises 
their application in oral drug delivery.
Intestinal mucus has a thickness of 100–800 µm and is composed of a complex 
network of highly branched glycoproteins, lipid, cellular and serum macromolecules, 
electrolytes, cells, and other cellular debris.8,9 The high viscoelasticity and adhesion 
of mucus, along with an abundance of possible particle-environment interactions, can 
severely retard the diffusion of nanocarriers or macromolecules through the mucus 
layer.10,11 Nanocarriers or macromolecules that do not efficiently penetrate the deeper International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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mucus layers and thereby reach the underlying   epithelium 
will be eliminated by mucus clearance mechanisms. 
Enhancing mucus-penetrating properties is considered to 
be of great importance in facilitating prolonged retention 
and more uniform distribution of drug carriers at mucosal 
surfaces.9,12,13 However, in order to improve cellular uptake 
and permeability in the epithelium, nanocarriers must pen-
etrate mucus, which is a longstanding challenge in mucous 
membrane drug delivery.
It has recently been reported that polystyrene and 
  polylactic-co-glycolic acid (PLGA) nanoparticles sufficiently 
coated with certain Pluronic® polymers or polyethylene 
glycol show lower degrees of mucoadhesion. This was 
proposed on the basis of a reduction of hydrophobic and/or 
electrostatic interactions, allowing for rapid penetration 
of the nanoparticles through human mucus.14–18 However, 
almost all of the studies of mucus-penetrating particles are 
focused on lung or cervicovaginal mucus, and very often use 
nonbiodegradable nanoparticles as drug delivery carriers. To 
the best of our knowledge, no mucus-penetrating liposomal 
formulation has been reported so far.
The aim of this study was to investigate the functionality 
of mucus-penetrating liposome formulations and explore 
their intestinal cellular uptake mechanism. Pluronic F127 
(PF127) was chosen as a liposomal modifier. Two types 
of PF127-modified liposomes ie, PF127-inlaid and PF127-
adsorbed, were designed. The mucus-penetrating proper-
ties of the PF127-modified liposomes were studied using a 
modified Franz diffusion cell. Cellular uptake studies of the 
two types of PF127-modified liposomes were conducted in 
Caco-2 cells and the uptake mechanism of the two types of 
PF127-modified liposomes was also investigated.
Materials and methods
Materials
Egg phosphatidylcholine (EPC) was purchased from QP Cor-
poration (Tokyo, Japan). PF127 was kindly donated by BASF 
(Ludwigshafen, Germany). RPMI 1640 medium and 0.25% 
trypsin/0.53 mmol/L EDTA were purchased from Invitrogen 
(Ontario, CA). Fetal bovine serum was obtained from Sijiqing 
Biological Engineering Materials Co Ltd (Zhejiang, China). 
Paraformaldehyde was purchased from Sinopharm Chemical 
Reagent Co Ltd (Shanghai, China). Penicillin, streptomycin, 
and 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochlo-
ride (DAPI) were purchased from Beyotime Institute of 
Biotechnology (Jiangsu, China). Lovastatin was purchased 
from Ruibang Laboratories (Zhejiang, China). Chlorpromaz-
ine was a generous gift from Grand Pharmaceutical Co Ltd 
(Wuhan, China). Methyl-β-cyclodextrin, filipin, cytochalasin D, 
coumarin 6, and Hank’s balanced salt solution (HBSS) 
were all purchased from Sigma-Aldrich (Saint Louis, MO). 
All other chemicals were of analytical reagent grade.
Preparation of liposomal carriers
Liposomes were prepared by the thin film hydration 
  technique. Two methods were used to incorporate PF127 
into the liposomes.19 Using the first method, the liposomal 
carrier was prepared by drying a chloroform solution con-
taining both lipid and PF127. Hydration of the film was then 
performed in distilled water for one hour at 25°C to a final 
lipid concentration of 5 mg/mL. The multilamellar vesicles 
were then extruded six times through 200 nm polycarbonate 
membranes (Avestin Inc, Canada). In the second method, 
liposomes were prepared as described earlier without addi-
tion of PF127. However, this was added after extrusion of the 
formed liposomes for absorption onto their surfaces.
In order to optimize the ratio of PF127 to EPC, the 
effect of different amounts of PF127 on the particle size 
and zeta potential of the preformed liposomes was studied. 
  Fluorescence labeling of the liposomal carriers was per-
formed using hydrophobic coumarin 6 during the preparation 
of thin lipid films. The marker was dissolved together with 
EPC in chloroform, and the liposomal carriers were prepared 
as described above.
characterization of liposomal carriers
The particle size, size distribution, and zeta potential of the 
liposomal carriers were determined at room temperature in 
distilled water using a Malvern Zetasizer NanoZS (Malvern 
Instruments, Worcestershire, UK). The morphology of 
the unmodified liposomes, PF127-inlaid liposomes, and 
PF127-adsorbed liposomes was analyzed using a transmis-
sion electron microscope (Philips CM200, Eindhoven, The 
Netherlands) at an accelerating voltage of 160 kV . Samples 
were deposited on carbon-coated copper grids and stained 
with phosphotungstic acid (1% w/v).20 To study the effect 
of temperature on the physicochemical properties of the 
liposomes, the solutions were aliquoted into two vials and 
stored for 2 hours at 4°C and 37°C, respectively. The particle 
sizes of the liposomes were determined using the Malvern 
Zetasizer NanoZS before and after incubation.
Detergent-resistant membrane level
The turbidity of the liposome samples with or without PF127 
modification exposed to Triton® X-100 was measured as 
absorbance by ultraviolet spectrophotometry at 400 nm and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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room temperature using a 4 cm light-path cell. Samples were 
occasionally stirred to ensure uniform mixing. The turbidity 
measurements were normalized to the control turbidity value 
of the liposome suspensions before treatment with Triton 
X-100. The effect of various doses of Triton X-100 on lipid 
turbidity was studied.
collection and preparation of native 
mucus samples
Native rat intestinal mucus was collected for the mucus-
penetrating study.21 Male Wistar rats which had been fasted 
overnight were sacrificed. The intestines were isolated and 
cut open, and all contents were removed by rinsing with 
cold saline. The mucus was then gently scraped with a 
cover slide and aliquoted in small glass/Eppendorf vials. 
The mucus collected was stored at −80°C until use. Prior to 
the mucus penetration experiments, the frozen sample vials 
were thawed over approximately 15 minutes to 37°C. All 
experiments were performed according to the regulations of 
the Animal Care and Use Committee of Shanghai Institute 
of Materia Medica.
In vitro mucus penetration study
The mucus (350 mg) was equilibrated in a constant tempera-
ture culture vibrator at 37°C for 15 minutes at a speed of 100 
rpm to ensure homogeneous dispersion of mucus.22,23 It was 
then placed in the donor chamber of a modified Franz diffu-
sion cell with a polycarbonate membrane (pore size 2 µm) 
located between the donor and receptor chambers to support 
the mucus. Then 50 µL of coumarin 6-loaded unmodified 
liposome, PF127-inlaid liposome, or PF127-adsorbed lipo-
some solutions were added onto the surface of the mucus 
and equilibrated for another 15 minutes in the vibrator 
under the same conditions. The receptor chamber was filled 
with phosphate-buffered saline. At fixed time intervals, 
1 mL samples from the receptor chamber were withdrawn 
and replaced with the same volume of prewarmed fresh 
phosphate-buffered saline. The samples were subsequently 
treated with Triton X-100 to lyse the liposomes and extract 
coumarin 6. The concentration of coumarin 6 was determined 
using a microplate reader.
The apparent permeability coefficient (Papp) was calcu-
lated using the following equation:
Papp = dQ/dt × 1/AC0
where dQ/dt is the flux of coumarin 6 through the intestinal 
mucus; C0 is the initial concentration of the coumarin 6 
in the donor chamber; and A is the area of the membrane 
between the donor chamber and the receptor chamber. The 
permeation enhancement ratio (R) was calculated by dividing 
the Papp of PF127-modified liposomes by that of unmodified 
liposomes.
cell culture
Caco-2 cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA), and the cells 
of passages 30–40 were used in this study. The cells were 
maintained in RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal bovine serum, 1% penicillin, and 1% 
streptomycin at 37°C in 5% CO2/95% air atmosphere in a 
humidified incubator. The cells were placed in a 75 cm2 flask 
at a density of 1 × 106 cells/flask. The medium was changed 
every 2–3 days and the cells were then harvested at 80% 
confluence with trypsin-EDTA and passaged.
cellular uptake study
Confocal laser scanning microcopy (CLSM) and flow 
cytometry (FACS) were used to assess intracellular uptake 
efficiency. For the CLSM analysis, the Caco-2 cells were 
seeded on glass cover slips in 24-well plates at a density of 
1 × 105 cells/cm2. After culturing for 24 hours, the culture 
medium was discarded and the cells were washed three 
times using HBSS. After 1 mL of liposomal formulations 
containing coumarin 6 1 µg/mL was added, the cells were 
incubated for 2 hours at 37°C. The sample solutions were then 
discarded and the cells were washed three times with HBSS. 
The cells were fixed with 4% paraformaldehyde solution and 
the cell nuclei were stained using DAPI. The samples were 
embedded in phosphate-buffered saline/glycerol (1:1) and 
examined under an inverted confocal microscope (FV1000, 
Olympus, Tokyo, Japan). The coumarin 6 and DAPI were 
investigated at 488/520 nm and 364/460 nm (excitation/
emission), respectively.
For FACS analysis, the cells were seeded in 12-well culture 
plates at a density of 1 × 105 cells/cm2. After 2 hours of incuba-
tion with the liposomal solutions, the cells were washed three 
times with HBSS and trypsinized for 2 minutes with 0.25% 
trypsin/0.53 mmol/L EDTA. Trypsinization was terminated by 
adding cold culture medium. The cells were detached gently 
by pipetting. After centrifugation, the treated samples were 
washed three times with HBSS and then transferred to FACS 
tubes. The cells were analyzed by FACS using BD FACS Cali-
bur fluorescent-activated flow cytometry and BD CellQuest 
software. This experiment was performed in triplicate and a 
total of 20,000 cells per sample were analyzed.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3154
Li et al
cellular association and uptake 
mechanism
In order to identify the endocytotic mechanisms of PF127-
modified liposomes, cellular uptake studies were performed in 
the presence of specific inhibitory agents for different types of 
endocytosis. Caco-2 cells were first incubated in HBSS con-
taining the specific inhibitory agents for one hour at 37°C, and 
subsequently exposed to the liposomal solutions for 2 hours at 
37°C. Control experiments were performed in HBSS alone fol-
lowed by cellular uptake studies for the different liposomes.
The effect of low temperature on the Caco-2 associa-
tion with different liposomal nanocarriers was investigated 
at 4°C. Methyl-β-cyclodextrin 10 mmol/L in the presence 
of lovastatin 1 µg/mL was used to deplete cholesterol,24 
which had been proved to inhibit caveolae-independent 
and clathrin-independent endocytosis. Filipin 1 µg/mL was 
used to inhibit caveolae-mediated or caveolae-like domain-
mediated endocytosis, while chlorpromazine 10 µg/mL 
inhibited clathrin-mediated endocytosis.25 Inhibition of 
macropinocytosis was achieved by incubation of cells with 
cytochalasin D 1 µg/mL.26
Results
Preparation and characterization  
of liposomal nanocarriers
Liposomal nanocarriers were obtained by the thin film hydration 
technique, as described in the Materials and methods section. 
Figure 1 shows the particle size and zeta potential of 
  liposomes in the presence of PF127 at molar ratios of 0:100, 
1:100, 2.5:100, 5:100, 10:100, and 15:100. The presence 
of PF127 neutralized the negative surface charge of the 
  liposomes. The particle size of the liposomes increased with 
an increase in the amount of PF127. A molar ratio of 5% was 
chosen to ensure a highly dense coating and partial surface 
charge neutralization of the liposomal surface with PF127 in 
order to improve the mucus-penetrating properties. However, 
this coating did not significantly change the particle size of 
the liposomes.
As shown in Table 1, unmodified liposomes had an 
average hydrodynamic diameter of 191.7 ± 11.2 nm with a 
polydispersity of 0.195 ± 0.011 and a negative zeta potential 
of approximately −8.9 mV . The incorporation of PF127 in 
the liposomes prepared by the two different methods did 
not have a distinct effect on particle size, but led to a sig-
nificant (P , 0.05) decrease in the zeta potential, which was 
reduced to −4.1 mV (PF127-inlaid) and −3.5 mV (PF127-
adsorbed).
As shown in Figure 2A, similar spherical morphologies 
were observed for unmodified liposomes, PF127-inlaid 
liposomes, and PF127-adsorbed liposomes, which indicates 
that PF127 did not alter the morphology of the liposomal 
nanocarriers.
It was necessary to study the effect of temperature on 
the physical properties of liposomes due to the thermo-
sensitive properties of PF127. The particle size change in 
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Table 1 Particle size, polydispersity, and zeta potential of un-
modified liposomes, Pluronic® PF127-inlaid liposomes, and Pluronic 
PF127-adsorbed liposomes
Formulation Mean diameter  
(nm)
PI Zeta-potential   
(mV )
Unmodified liposomes 191.7 ± 11.2 0.195 ± 0.011 −8.93 ± 1.67
PF127-inlaid liposomes 185.6 ± 8.9 0.103 ± 0.005 −4.12 ± 2.32
PF127-adsorbed  
liposomes
203.2 ± 13.7 0.206 ± 0.034 −3.54 ± 1.37
Note: Data were shown as mean ± standard deviation (n = 3).
Abbreviation: PI, polydispersity index.
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Figure 2 (A) Transmission electron micrographs of unmodified liposomes, Pluronic® F127-inlaid liposomes and Pluronic F127-adsorbed liposomes. (B) Particle size change 
in liposomes after incubation at 37°c for 2 hours and 4°c for 2 hours or 12 hours. (C) Influence of Triton X-100® on relative absorbance at 400 nm of unmodified liposomes 
(), PF127-inlaid liposomes (•), and PF127-adsorbed liposomes ().
the liposomes after incubation at 4°C and 37°C for 2 hours 
is shown in Figure 2B. These results show that although 
modified with the same thermosensitive polymer, the two 
PF127-modified liposomes had different thermosensitive 
properties. When kept at 4°C for 2 hours, the particle size 
of the PF127-inlaid liposomes increased from 185 nm to 
227 nm, whereas the PF127-adsorbed liposomes converted 
into aggregates at a micrometer level. Liposomal aggrega-
tion was clearly observed in both PF127-inlaid liposomes 
and PF127-absorbed liposomes after 12 hours of incubation 
at 4°C. However, none of the PF127-modified liposomes 
changed significantly at 37°C. The results indicated that 
the thermosensitive properties of PF127 were partially 
compromised when incorporated into liposomes during the 
preparation period, while the construction of PF127-adsorbed 
liposomes at low temperature retained thermosensitivity.
Detergent-resistant membrane level 
altered by PF127
The ability of PF127 to alter detergent resistance at the mem-
brane level in the mixed liposome was evaluated, given that 
the ability to resist detergent extraction is a characteristic of 
formation of dense gel/ordered domains in the liposome.27 
Incorporation of PF127 into liposomes caused a significant 
shift of the turbidity curve in the presence of Triton X-100. 
A slower decrease in turbidity was observed for PF127-inlaid 
liposomes and PF127-adsorbed liposomes (Figure 2C), which 
indicated that PF127 was able to protect domain lipids from 
being solubilized by Triton X-100. The effect was more 
significant for PF127-inlaid liposomes, which suggested that 
PF127-inlaid liposomes caused highly ordered and tightly 
packed domains compared with unmodified liposomes and 
PF127-adsorbed liposomes.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In vitro intestinal mucus-penetrating 
studies
The cumulative amounts of coumarin 6-loaded liposomal 
carriers penetrating through the mucus layer are shown in 
Figure 3. Comparing unmodified liposomes with the two 
types of PF127-modified liposomes, an enhanced perme-
ability of coumarin 6 was found for modified liposomes. Due 
to the hydrophobic properties of coumarin 6, the association 
between the marker and liposomal formulations was quite 
strong. The entrapment efficiency of coumarin 6 in the lipo-
somal carriers was measured to be approximately 100%, and 
less than 2.0% of coumarin 6 was released from the liposomal 
carriers after 4 hours of incubation at 37°C in phosphate-
buffered saline (data not shown). Therefore, it is reasonable to 
assume that coumarin 6 was cotransported with the liposomal 
nanocarriers,16 and thus it is acceptable to use coumarin 6 as 
a marker of liposomal transport in the Franz diffusion cell. 
The cumulatively transported amounts of coumarin 6 in the 
two types of PF127-modified liposomes were increased by 
more than six-fold compared with unmodified liposomes 
(Figure 3B). As a control, permeability of coumarin 6-loaded 
unmodified liposomes was investigated in the absence of rat 
intestinal mucus in the donor chamber of the Franz diffusion 
cell. As shown in Figure 3B, more than 95% of coumarin 6 
penetrated through the polycarbonate membrane in this case. 
This indicates that native rat intestinal mucus has the barrier 
properties of a liposomal formulation.
The Papp of coumarin 6-loaded liposomal carriers and the 
permeation enhancement ratio of the two types of PF127-
modified liposomes are presented in Table 2. The results 
show that the two types of PF127-modified liposomes 
increased permeation of coumarin 6 as compared with 
unmodified liposomes. The Papp of coumarin 6-loaded PF127-
inlaid liposomes and PF127-adsorbed liposomes was almost 
5–7-fold higher than that of unmodified liposomes. However, 
there was no significant difference in Papp observed between 
PF127-inlaid liposomes and PF127-adsorbed liposomes. 
This indicates that PF127 improved the mucus-penetrating 
properties regardless of the type of incorporation between 
polymer and liposomes.
cellular uptake study in caco-2 cells
Caco-2 uptake of the liposomal carriers was visualized using 
CLSM. As shown in Figure 4 (left), the Caco-2 cellular 
uptake efficiency of coumarin 6 was influenced by the type 
of PF127 modification in the liposomes. The PF127-inlaid 
liposomes showed a higher association efficiency with the 
cells than did the unmodified liposomes. Stronger green 
fluorescence was observed to be associated with Caco-2 cells 
in the PF127-inlaid liposome group compared with the 
unmodified liposome group, whereas the cellular uptake of 
liposomes was decreased when PF127 was simply adsorbed 
onto the surface of the liposomes. The results from FACS, 
as shown in Figure 4 (right), strongly support the findings of 
the CLSM study. For the PF127-inlaid liposomes, the cel-
lular association efficiency was enhanced by approximately 
1.5-fold compared with unmodified liposomes, whereas the 
cellular association efficiency was decreased to less than 
70% when PF127 was merely attached to the surface of the 
liposomes by adsorption.
As mentioned above, the release of coumarin 6 from the 
liposomal formulation after 4 hours of incubation at 37°C 
in phosphate-buffered saline was usually less than 2.0% due 
to its hydrophobic properties. Therefore, the contribution of 
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Table 2 Permeability value for coumarin 6-loaded unmodified 
liposomes, Pluronic® PF127-inlaid liposomes and Pluronic PF127-
adsorbed liposomes transported through intestinal mucus
Formulation Papp (×10-7cm/s) R
Unmodified liposome 1.88 ± 0.23 –
PF127-inlaid liposomes 12.37 ± 1.05 6.58 ± 0.56
PF127-adsorbed liposomes 11.64 ± 1.16 5.84 ± 0.62
Notes: Data shown as mean ± standard deviations (n = 3).
Abbreviations: P app,  the  apparent  permeability  coefficient;  R,  permeation 
enhancement ratio.
influenced by filipin, with a reduction in cellular association 
of about 50% (Figure 5A), while the effects of methyl-β-
cyclodextrin/lovastatin, chlorpromazine, and cytochalasin D 
on the cellular association of unmodified liposomes was 
negligible. This indicates that in addition to pathways that 
are not energy-dependent, caveolae-mediated endocytosis 
is also involved in the uptake of unmodified liposomes by 
Caco-2 cells. Preincubation of Caco-2 cells with filipin 
1 µg/mL resulted in significant reduction of the cellular 
association of PF127-inlaid liposomes (approximately 50%). 
However, it did not completely inhibit active uptake of the 
liposomes when compared with the association efficiency 
at 4°C (Figure 5B). Chlorpromazine 10 µg/mL also had a 
distinct effect on the cellular association of PF127-inlaid 
liposomes. As shown in Figure 5B, the total amount of cell-
associated liposomes was markedly reduced to approximately 
65%, indicating that clathrin-mediated endocytosis was also 
involved in the cellular uptake of PF127-inlaid liposomes. 
For PF127-adsorbed liposomes, the mechanism was almost 
the same as that for unmodified liposomes. The cellular 
uptake decreased to 50% when incubated with filipin 
1 µg/mL, while other inhibitory agents showed no significant 
effect on the cellular uptake of PF127-adsorbed liposomes 
(Figure 5C).
Discussion
Modification of lipid systems by polymers may improve the 
efficiency of liposomal drug delivery systems by enhancing 
their physicochemical characteristics, eg, physical stability, 
encapsulation efficiency, bioadhesiveness, and “stealthing”. 
A typical example is polyethylene glycol-conjugated lipid 
systems, which can “stealth” and stabilize liposomes, thereby 
prolonging the circulation half-life in vivo. Other polymers 
commonly used for modification of liposomal formula-
tions are Poloxamers and Pluronics, a group of triblock 
copolymers with an amphiphilic nature. Different from 
PEGylated liposomes, the triblock copolymer in Pluronic-
modified liposomes is either incorporated into or adsorbed 
onto the liposomal surface. This has been described by 
techniques such as nuclear magnetic resonance, differential 
scanning calorimetry, and dynamic light scattering.29,30 
  Further, it is well known that Pluronics, in aqueous solution, 
exist either as monomers or as self-assembled micelles. This 
behavior depends on the concentration and temperature of the 
surroundings. Hence when formulating the copolymer with 
liposomes, the Pluronics concentration and the temperature 
applied are two crucial factors determining the final composi-
tion and characteristics of the liposomes. In this study, PF127 
free coumarin 6 to the total cellular association of the carriers 
was negligible. In the Caco-2 cell uptake study, coumarin 6 
detected inside the cells could have been derived from cel-
lular association of the liposomal carriers rather than the free 
marker released from the liposomal formulations. These find-
ings indicate that the mechanism of cellular uptake for these 
two types of PF127-modified liposomes was different, even 
though both formulations improved the mucus-penetrating 
properties relative to unmodified liposomes.
Uptake mechanism of liposomal carriers 
in caco-2 cells
The cellular uptake mechanism of the two types of PF127-
modified liposomes were investigated using different inhib-
iting agents and different temperatures. The effect of low 
temperature on the Caco-2 association with the different 
liposomal carriers was evaluated by incubating the differ-
ent formulations at 4°C. The same liposomal nanocarriers 
treated with HBSS for one hour were used as the control 
group. As shown in Figure 5, a significant reduction in 
Caco-2 cell association efficiency was observed at 4°C for 
all three formulations as compared with that at physiological 
temperature. The cellular association of PF127-inlaid lipo-
somes and PF127-adsorbed liposomes decreased significantly 
(P , 0.01) to 20% and 35%, respectively, while the unmodi-
fied liposomes still had a cellular association of about 50% as 
compared with the control group (P , 0.05). These results 
indicate that the cellular uptake of PF127-inlaid liposomes 
and PF127-adsorbed liposomes relied more on an energy-
dependent pathway than did the unmodified liposomes.
The effect of nonspecific metabolic inhibitors on the 
cellular association of the liposomes was also investigated. 
It was reported that liposomes could be internalized into 
cells by different mechanisms, including clathrin-dependent 
endocytosis, caveolae-dependent endocytosis, macrocytosis, 
and fusion, according to the type of cell, composition, surface 
charge, and size of the liposome.25,28 In our study, the cellular 
association of the unmodified liposomes was significantly International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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was formulated with EPC liposomes at a concentration of 
0.42% (w/v). The preparation of PF127-modified liposomes 
were conducted using two methods at 25°C. Because the 
concentration of 0.42% (w/v) is below the critical micelle 
concentration of PF127 at 25°C, which is 0.7% (w/v),31 
PF127 are expected to be incorporated into the liposomes 
as monomers. This was confirmed by transmission electron 
microscopy and dynamic light scattering, both showing no 
formation of micelles. A schematic diagram of the PF127-
modified liposomes is shown in Figure 6, for PF127-inlaid 
liposomes, with PF127 actively involved in liposomal bilayer 
construction and distributed evenly across the bilayers, 
in contrast with PF127 absorbed liposomes, with PF127 
absorbed solely on the surface of the liposome.
The detergent resistance experiment showed that PF127-
modified liposomes were stronger liposomal structures than 
Figure 4 Confocal laser scanning microscopy and flow cytometry histogram of cellular uptake of coumarin 6-loaded liposomes, Pluronic® F127-inlaid liposomes, and Pluronic 
F127-adsorbed liposomes (green fluorescence) into Caco-2 cells. Nuclear staining was performed by DAPI (blue staining). The image was representative of three experiments 
with similar results.
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normal liposomes at the concentration of PF127 used in this 
study. These results indicate that PF127 modification could 
improve the stability of the liposome when used in vivo. 
PF127 stabilization possibly prevents the liposomal mem-
brane from being distorted by surfactants, eg, the bile salts 
abundantly distributed in the gastrointestinal tract. Moreover, 
the improved rigidity of the liposomes may decrease drug 
leakage from nanocarriers, thus improving the stability of 
incorporated drugs. This would be of particular interest for 
enzyme-sensitive or acid-sensitive drug molecules.
Mucus-penetrating properties  
of PF127-modified liposomes
Limited diffusion in intestinal mucus has been found to be 
one of the main limitations for drug delivery via the mucus 
membrane using nanocarriers like polymeric nanoparticles 
and liposomes. Our results indicate that the incorporation of 
PF127 into EPC liposomes facilitated their diffusion into rat 
intestinal mucus. Diffusion of unmodified liposomes through 
the intestinal mucus in the donor chamber of this experimental 
model was less than 10% within one hour, whereas the diffu-
sion efficiency increased to 95% during the same time period 
across the polycarbonate membrane support alone. This sug-
gests that diffusion of unmodified liposomes was restricted 
by native rat intestinal mucus. Further, it indicates that the 
modified Franz diffusion cell is a reliable model for evaluating 
the mucus-penetrating properties of nanocarriers.
Chen et al have reported that rat intestinal mucus is a bar-
rier to diffusion of cyclosporin A-loaded liposomes.32 It was 
shown that most of the cyclosporin A-loaded liposomes were 
stranded in the rat intestinal mucus and unable to reach the 
intestinal wall. In our study, modification of liposomes with 
PF127 significantly enhanced diffusion efficiency through the 
native rat intestinal mucus. Compared with unmodified lipo-
somes, the Papp of PF127-modified liposomes was increased 
by 5–7-fold, and the percentage of cumulative amounts of 
coumarin 6 transported through the polycarbonate membrane 
was increased by six-fold. This increase might be due to 
the distribution of the hydrophilic polyoxyethylene part of 
PF127 on the surface of liposomes. This reduces the hydro-
phobic and electrostatic interactions of liposomal systems 
with mucin, allowing the nanocarriers to migrate through 
the mucus medium. Therefore, mucus clearance of the lipo-
somes was minimized. However, inlaying or adsorbing the 
PF127 onto the liposomes did not seem to matter in terms 
of mucopenetration. This may due to the surface presence 
of polyoxyethylene chains of PF127, resulting in general 
hydrophilicity and shielding of surface charges.
caco-2 cellular uptake
Because a hydrophilic shell is usually biologically inert 
and will weaken the interaction of nanocarriers with a 
cell membrane,12,33 the cellular uptake of PF127-modified 
liposomes was investigated using Caco-2 cells. The results 
showed that, when loaded in PF127-inlaid liposomes, the 
cellular uptake of coumarin 6 was significantly increased 
as compared with unmodified liposomes. However, cellular 
uptake of coumarin 6 was decreased when it was formulated 
with PF127-absorbed liposomes. These results indicate that 
the cellular uptake efficiency of PF127-modified liposomes 
was directly affected by the modification method. The two 
modification methods resulted in a different incorporation 
pattern of PF127 in the liposomes. It has been reported that 
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addition of PF127 during vesicle formation (PF127-inlaid 
liposomes) resulted in polymer incorporation in both the 
inner and outer leaflets of the lipid bilayer, whereas all PF127 
was associated only with the outer leaflet of the bilayer when 
PF127 was added after vesicle formation (PF127-absorbed 
liposomes) as illustrated in Figure 6.19
It is widely accepted that Pluronic polymers can stabilize 
and seal damaged lipid bilayer membranes.34–36 Considering 
that the PF127 is adsorbed on the outer leaflet of the bilayer 
(PF127-adsorbed liposomes), it may be easily lost by simple 
diffusion. It might then interact with the cell membrane, 
altering the membrane fluidity and membrane interaction, 
and finally stabilizing the membrane structure. Hence the 
cellular uptake of liposomes was decreased. This is strongly 
supported by the fact that the cellular uptake mechanism 
of PF127-adsorbed liposomes was quite similar to that of 
the unmodified liposomes. Sarah et al37 have reported both 
impaired Caco-2 cell viability and monolayer integrity when 
Pluronic F68 was used to deliver poorly soluble drugs.
However, for PF127-inlaid liposomes, when PF127 was 
inserted into both the inner and outer leaflet of the bilayer, the 
interaction between PF127 and the vesicles was much stronger. 
Thus, dissociation of PF127 from liposomes is unlikely to 
happen. As for the mechanism of cellular uptake of PF127-
inlaid liposomes, in addition to the caveolae-mediated uptake 
pathway, clathrin-mediated endocytosis had been introduced, 
as shown in the Caco-2 cell study as well. This mechanism 
of cellular uptake for PF127-inlaid liposomes is similar to 
that of Pluronic micelles. It has been reported that Pluronic 
P85 micelles were internalized by Caco-2 cells via clathrin-
mediated and caveolae-mediated endocytosis.38 A significant 
reduction in Caco-2 cell association efficiency at 4°C was 
observed in both PF127-inlaid liposomes and PF127-absorbed 
liposomes as compared with that at 37°C. For PF127-adsorbed 
liposomes, this may due to aggregation at 4°C. Because the 
particle size change for PF127-inlaid liposomes was less 
obvious than for PF127-adsorbed liposomes, the cellular 
uptake efficiency of PF127-inlaid liposomes should be less 
affected by low temperature. However the results showed 
that cellular uptake was more inhibited by low temperature, 
which again confirmed that cellular uptake of PF127-inlaid 
liposomes relied more on an energy-dependent pathway.
Most of the recent studies of polymer-modified nano-
carriers were conducted by simply incubating nanocarriers 
with a polymer solution to enable absorption of the polymer 
onto the surface of the nanocarriers.39-41 Our studies clearly 
demonstrate that different modification methods result 
in different liposomal constructs with different cellular 
uptake efficiency.
Conclusion
Two types of mucus-penetrating liposomal formulations, ie, 
PF127-laid liposomes and PF127-adsorbed liposomes, were 
designed by incorporating PF127 with EPC lipids prior to 
or after vesicle formation. In vitro mucus-penetrating stud-
ies showed that the two types of PF127-modified liposomes 
possessed similar mucus-penetrating efficiency, and PF127 
could significantly improve the mucus-penetrating properties 
of EPC liposomes in native rat intestinal mucus. A modi-
fied Franz diffusion cell model was established, which was 
demonstrated to be useful when studying mucus-penetrating 
properties of nanocarrier systems, eg, liposomes. In Caco-2 
cellular uptake studies, PF127-inlaid liposomes exhibited 
higher cellular uptake efficiency when compared with PF127-
adsorbed liposomes as well as unmodified liposomes. The dis-
tinct cellular uptake mechanisms of PF127-inlaid liposomes 
from PF127-adsorbed liposomes were most likely due to the 
different constructs of the two types of PF127-modified lipo-
Unmodified liposomes PF127-inlaid liposomes  PF127-adsorbed liposomes
Figure 6 schematic presentation of different liposomal nanocarriers. green represents the polyethylene oxide chain of Pluronic® F127; red represents the polyoxypropylene 
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Dovepress 
Dovepress
3161
Mucus-penetrating liposomal oral drug delivery system
somes produced. Taking both mucus-penetrating properties 
and cellular uptake into account, PF127-inlaid liposomes 
were shown to be very promising in drug delivery via mucus 
membranes of different cavities, eg, the intestine.
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